PBM

Psyence Biomedical Ltd. (PBM) | Rumor.io

Psyence Biomedical

PBM

Attention (50-day avg)0%

Attention rank (50-day avg)#2,192

Bullish sentiment (50-day avg)94%

Price to earnings ratio0.04

Market capitalization21.6M

Earnings per share-11.7

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-6.9M

Social

What share of all stock conversation is about PBM?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% +0	0% 0

Sep 14

Psyence Biomedical Ltd. (PBM) establishes Texas Ibogaine Research Corporation to advance U.S. ibogaine development, per its 6-K press release.
A highly anticipated FDA hearing on psychedelic drug development is taking place, with discussion of provider training, patient safety, access issues, and best practices for data collection and standardization of psychedelic medications.
PBM's establishment of the Texas Ibogaine Research Corporation is expected to speed the regulatory and application processes for ibogaine supply contracts significantly, with potential for a breakout in the coming weeks.

Generated by AI

Sentiment

Of the messages about PBM that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% 0	95% +3.82	78.16% -5.68
Bearish	—	0% 0	5% -3.82	21.84% +5.68

Bullish· Apr 29

$PBM is due for a sharp rebound as its RSI is way oversold, making it a prime buy opportunity.
Institutional shorts may be facing consequences for their actions, potentially leading to a reversal in the stock's price.
$PBM has the potential to be acquired by larger companies due to its unique product offerings and ongoing trials, making it a prime target for a buyout.

Bearish· May 1

$PBM's recent spike was likely a result of short covering and a bull trap, rather than genuine buying interest.
The stock's volatility is causing investors to lose money, with some experiencing significant losses due to its unpredictable price movements.
$PBM's performance is comparable to other stocks like $AKAN, which may suggest a similar downward trend or lack of growth potential.

Generated by AI

Topics

Of the messages about PBM that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	100%	2.24%
Technical Analysis	0%	0%	0%	1.01%
Analysts	0%	0%	0%	2.19%
Controversies	0%	0%	0%	0%
Earnings	0%	0%	0%	45.65%
Macro	0%	0%	0%	48.92%

Announcements· Apr 20

Psyence BioMed has a ready-to-ship supply of GMP-compliant ibogaine doses, removing a key bottleneck for in-house development and academic or commercial partners.
President Trump signed an executive order to accelerate medical treatments for serious mental illness, including ibogaine research, with a reported $50 million commitment.
Psyence BioMed has secured ethically sourced African ibogaine supply and produced GMP-compliant ibogaine HCl, giving it control over multiple parts of the pipeline and leverage in the ibogaine market.

Technical Analysis· Jul 25

$PBM has been identified as potentially overbought, with a 200%+ move in after-hours trading, and may be due for a massive pullback.
The stock has reclaimed critical support at $0.58 and is expected to move higher, potentially reaching $0.75.
$PBM has formed a cup and handle pattern on the 5 and 15-minute charts, and a bull flag on the 5-minute chart, indicating potential for further price increases.

Generated by AI

Community

Of the messages about PBM, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	69.23%	79.17%	83.93%	11.43%
Newcomers	30.77%	20.83%	16.07%	88.57%

Regulars· Aug 18

The University of Miami has provided the federal government with the original 1994 Ibogaine IND application, potentially accelerating psychedelic treatments for veterans.
Psyence Biomedical's ($PBM) stock is strongly correlated with other psychedelic companies, such as $CMND, which have seen significant price increases on news related to this sector.
The low market capitalization and tightly held float of Psyence Biomedical make it a potentially volatile stock, with the potential for significant price swings on news related to the company or its sector.

Newcomers· Aug 18

The University of Miami has provided the federal government with the original 1994 Ibogaine IND application, which is seen as a historic step toward accelerating psychedelic treatments for veterans.
There is a possibility that veterans suffering from serious mental illness will have the right to try Ibogaine treatments in the U.S. after President Trump's announcement.
The author is watching for profit-taking after the recent run-up in price, as valuation looks stretched and fundamentals remain weak.

Generated by AI

News

Psyence BioMed unit signs term sheet for U.S. ibogaine rights

1d agoInvesting.com

Psyence BioMed Announces Exclusive U.S. Ibogaine Licence for Texas Ibogaine Research Corporation

2d agoYahoo! Finance Canada

Psyence BioMed invests up to $5M in PsyLabs, plans ibogaine trial By Investing.com

6d agoInvesting.com

Psyence BioMed Announces Strategic Ibogaine Investment

Transactions include an investment of up to US$5 million in PsyLabs and an approximately US$9 million value-matched share exchange Highlights The Company is actively advancing plans for a potential ibogaine clinical trial in Texas for Opioid Use Disorder (OUD).Texas Ibogaine Research Corporation (TIRC), a dedicated U.S. subsidiary of Psyence BioMed, has been established for its planned ibogaine development activities in the US.Psyence BioMed has agreed to invest up to US$5 million in PsyLabs, of

7d agoYahoo! Finance Canada

Psyence BioMed Establishes Texas Ibogaine Research Corporation to Advance U.S. Ibogaine Development

Texas-based company is designed to coordinate U.S. development, pharmaceutical-grade supply and potential clinical sponsorship activities through a dedicated Psyence BioMed entityHIGHLIGHTS Texas-based company established as dedicated U.S. vehicle for regulated ibogaine developmentPositioned to hold U.S. rights to PsyLabs’ pharmaceutical-grade ibogaine, subject to completion of definitive licensing arrangementsDesigned to coordinate supply, manufacturing, regulatory and potential clinical develo

16d agoYahoo Finance

Psyence BioMed responds to Trump ibogaine announcement

1mo agoInvesting.com

Also Discussed

Investors talking about PBM also mention

#	Name	Attention
1	Clearmind Medicine Inc. Common SharesCMND	0%new
2	Semilux International Ltd.SELX	0%new
3	Roma Green Finance LimitedROMA	0%0
4	UOKA - MDJM Ltd	——
5	BT Brands, Inc.BTBD	0%0
6	Falcon's Beyond Global, Inc. Class A Common StockFBYD	0%new
7	CERO - CERo Therapeutics Holdings, Inc.	——
8	SMX (Security Matters) Public Limited CompanySMX	0%+0
9	Silexion Therapeutics Corp.SLXN	0.03%-0.01
10	AdvisorShares Psychedelics ETFPSIL	0.02%+0.01

Psyence Biomedical Ltd.

Healthcare
Biotechnology

Psyence Biomedical Ltd. is a Toronto-based biopharmaceutical company focused on developing botanical psilocybin-based medicines for mental health and palliative care settings. The company’s current work centers on nature-derived psychedelic therapeutics designed to address unmet needs in conditions such as adjustment disorder, anxiety, depression, grief, and related psychological distress in patients facing serious illness. Its lead candidate is being evaluated in clinical studies as a capsule formulation of naturally sourced psilocybin, reflecting the company’s emphasis on standardized, non-synthetic drug development. Psyence Biomedical operates within the broader life sciences and healthcare markets, combining drug development, clinical research, and commercialization efforts around psychedelic medicine. Through this specialization, the company occupies a niche position in the emerging field of evidence-based psychedelic therapeutics, with a focus on supportive care applications rather than general consumer health products.

Website

Location

121 Richmond Street West

Toronto, ON, M5H 2K1

Canada

Social

What share of all stock conversation is about PBM?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% new	0% +0	0% +0	0% 0

Sep 14

Psyence Biomedical Ltd. (PBM) establishes Texas Ibogaine Research Corporation to advance U.S. ibogaine development, per its 6-K press release.
A highly anticipated FDA hearing on psychedelic drug development is taking place, with discussion of provider training, patient safety, access issues, and best practices for data collection and standardization of psychedelic medications.
PBM's establishment of the Texas Ibogaine Research Corporation is expected to speed the regulatory and application processes for ibogaine supply contracts significantly, with potential for a breakout in the coming weeks.

Generated by AI

Sentiment

Of the messages about PBM that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	100% 0	95% +3.82	78.16% -5.68
Bearish	—	0% 0	5% -3.82	21.84% +5.68

Bullish· Apr 29

$PBM is due for a sharp rebound as its RSI is way oversold, making it a prime buy opportunity.
Institutional shorts may be facing consequences for their actions, potentially leading to a reversal in the stock's price.
$PBM has the potential to be acquired by larger companies due to its unique product offerings and ongoing trials, making it a prime target for a buyout.

Bearish· May 1

$PBM's recent spike was likely a result of short covering and a bull trap, rather than genuine buying interest.
The stock's volatility is causing investors to lose money, with some experiencing significant losses due to its unpredictable price movements.
$PBM's performance is comparable to other stocks like $AKAN, which may suggest a similar downward trend or lack of growth potential.

Generated by AI

Topics

Of the messages about PBM that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	100%	100%	100%	2.24%
Technical Analysis	0%	0%	0%	1.01%
Analysts	0%	0%	0%	2.19%
Controversies	0%	0%	0%	0%
Earnings	0%	0%	0%	45.65%
Macro	0%	0%	0%	48.92%

Announcements· Apr 20

Psyence BioMed has a ready-to-ship supply of GMP-compliant ibogaine doses, removing a key bottleneck for in-house development and academic or commercial partners.
President Trump signed an executive order to accelerate medical treatments for serious mental illness, including ibogaine research, with a reported $50 million commitment.
Psyence BioMed has secured ethically sourced African ibogaine supply and produced GMP-compliant ibogaine HCl, giving it control over multiple parts of the pipeline and leverage in the ibogaine market.

Technical Analysis· Jul 25

$PBM has been identified as potentially overbought, with a 200%+ move in after-hours trading, and may be due for a massive pullback.
The stock has reclaimed critical support at $0.58 and is expected to move higher, potentially reaching $0.75.
$PBM has formed a cup and handle pattern on the 5 and 15-minute charts, and a bull flag on the 5-minute chart, indicating potential for further price increases.

Generated by AI

Community

Of the messages about PBM, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	69.23%	79.17%	83.93%	11.43%
Newcomers	30.77%	20.83%	16.07%	88.57%

Regulars· Aug 18

The University of Miami has provided the federal government with the original 1994 Ibogaine IND application, potentially accelerating psychedelic treatments for veterans.
Psyence Biomedical's ($PBM) stock is strongly correlated with other psychedelic companies, such as $CMND, which have seen significant price increases on news related to this sector.
The low market capitalization and tightly held float of Psyence Biomedical make it a potentially volatile stock, with the potential for significant price swings on news related to the company or its sector.

Newcomers· Aug 18

The University of Miami has provided the federal government with the original 1994 Ibogaine IND application, which is seen as a historic step toward accelerating psychedelic treatments for veterans.
There is a possibility that veterans suffering from serious mental illness will have the right to try Ibogaine treatments in the U.S. after President Trump's announcement.
The author is watching for profit-taking after the recent run-up in price, as valuation looks stretched and fundamentals remain weak.

Generated by AI

Psyence Biomedical

Social

Sep 14

Bullish· Apr 29

Bearish· May 1

Announcements· Apr 20

Technical Analysis· Jul 25

Regulars· Aug 18

Newcomers· Aug 18

Psyence BioMed unit signs term sheet for U.S. ibogaine rights

Psyence BioMed Announces Exclusive U.S. Ibogaine Licence for Texas Ibogaine Research Corporation

Psyence BioMed invests up to $5M in PsyLabs, plans ibogaine trial By Investing.com

Psyence BioMed Announces Strategic Ibogaine Investment

Psyence BioMed Establishes Texas Ibogaine Research Corporation to Advance U.S. Ibogaine Development

Psyence BioMed responds to Trump ibogaine announcement

Also Discussed

Psyence Biomedical Ltd.

Company Information

Location

Psyence BioMed unit signs term sheet for U.S. ibogaine rights

Psyence BioMed Announces Exclusive U.S. Ibogaine Licence for Texas Ibogaine Research Corporation

Psyence BioMed invests up to $5M in PsyLabs, plans ibogaine trial By Investing.com

Psyence BioMed Announces Strategic Ibogaine Investment

Psyence BioMed Establishes Texas Ibogaine Research Corporation to Advance U.S. Ibogaine Development

Psyence BioMed responds to Trump ibogaine announcement

Also Discussed

Social

Sep 14

Bullish· Apr 29

Bearish· May 1

Announcements· Apr 20

Technical Analysis· Jul 25

Regulars· Aug 18

Newcomers· Aug 18